Peptides A-Z · Research Guide
This article offers a neutral, evidence based look at peptides that stimulate growth hormone release. It explains which compounds are approved, where evidence is limited, and how to…
The focus is practical: identify the single peptide with an FDA labeled use, summarize trial and review findings for common off label secretagogues, and give a decision framework you can use to match goals with evidence and regulatory realities.
In this guide we use the term hgh peptides to mean peptide compounds that stimulate growth hormone release, broadly called growth hormone secretagogues. These include FDA labeled drugs, where available, and a larger group of investigational secretagogues that act at the ghrelin receptor or related pathways. For readers who want the scientific review background, clinical overviews describe these agents and their mechanisms in accessible terms Frontiers review.
When we ask which product is best we do not mean a universal answer. Best depends on three linked questions: is there a labeled medical indication, what is the strength of clinical evidence for the intended goal, and can you verify product quality and compliance with rules that apply to you. This guide treats labeled approval, trial evidence and sourcing transparency as the primary decision axes.
Roadmap: the article first explains basic mechanisms and regulatory status, then summarizes clinical evidence, covers safety and sourcing concerns, and ends with a decision framework and practical scenarios so you can compare options without treating this as medical advice.
At a basic level, many hgh peptides act as secretagogues by stimulating receptors that trigger endogenous growth hormone release. Some compounds mimic the activity of ghrelin and bind the ghrelin receptor, while others act through related hypothalamic pathways. Reviews summarize these classes and the molecular targets researchers study Frontiers review and our GH secretagogues primer.
Most peptides in this category are administered by subcutaneous injection to achieve predictable absorption and avoid digestive breakdown. Subcutaneous dosing affects onset and duration compared with oral agents, and the delivery route is a common reason trial protocols specify injections rather than other routes.
Mechanistic data can explain how a compound raises GH or IGF-1 in the short term, but it does not by itself prove long term clinical benefit. Many mechanistic studies measure surrogate endpoints such as transient IGF-1 changes, which are useful but not definitive for outcomes like sustained body composition change or long term safety.
Tesamorelin is the only growth hormone releasing peptide with an FDA labeled indication; it is approved for HIV associated abdominal lipodystrophy and is described as a labeled therapy in the prescribing information Egrifta prescribing information.
Tesamorelin is the only growth hormone releasing peptide with FDA approval for HIV associated abdominal lipodystrophy and a labeled dose of 2 mg subcutaneously once daily; other secretagogues are investigational and lack the same regulatory backing.
The product label specifies the dose as 2 mg administered subcutaneously once daily, and the label includes monitoring and contraindication details that are part of standard clinical use for that indication Egrifta product information.
Regulatory approval matters because it signals that specific trials and safety reviews were completed for a defined patient population and dosing regimen, which differs from experimental or off label use that lacks the same evidence base.
Off label use means a compound is used for purposes, doses or populations that are not listed in an official regulatory label. Many secretagogues are discussed online and in practitioner circles as off label options for anti aging, body composition or performance goals, but that usage is not the same as an approved medical indication.
Sermorelin and ipamorelin are examples of GH secretagogues that are commonly used off label or experimentally for anti aging, fat loss or muscle oriented goals. Systematic and narrative reviews note these agents have been studied but that high quality randomized controlled trial evidence for these indications remains limited Systematic review.
Because these uses are off label they carry additional uncertainty about dose, duration and monitoring. Regulatory and consumer safety advisories also highlight that products sold online may not match label claims, which increases risk for users considering off label options FDA consumer warning.
Tesamorelin’s approval was supported by trials aimed at the specific problem of HIV associated abdominal fat redistribution, and those trial endpoints and results are described in the prescribing documentation supporting labeling Egrifta prescribing information.
For sermorelin, ipamorelin and related secretagogues the literature shows smaller trials, variable endpoints and limited long term follow up. Systematic reviews emphasize that evidence for broad anti aging or general fat loss claims is not robust, and further well controlled randomized trials are needed to establish clear benefits and risks Frontiers review.
Readers should note the product listing is a marketplace overview rather than a clinical endorsement. Use product catalogs for comparison and specification checks, but pair that with independent evidence and regulatory guidance when evaluating suitability.
Competitive athletes should be clear that the World Anti Doping Agency lists GH secretagogues and related peptides as prohibited in competition, and that these rules are regularly updated on the official prohibited list WADA Prohibited List.
Beyond doping rules, regulators have repeatedly warned about online peptide markets and the risks of mislabeling and contamination in unverified products, which is a separate safety issue that can affect anyone purchasing unregulated compounds FDA consumer warning.
Regulatory advisories highlight several recurring problems in online peptide supply chains, notably mislabeling, variable purity and contamination with undeclared substances. These issues are documented in consumer warnings that caution buyers about trusting unverified online claims FDA consumer warning.
Because many commercial peptide listings are not subject to the same manufacturing oversight as prescription medicines, regulators advise that product identity and purity may not match label information and that this difference can create health risks, especially when products are used in clinical contexts or mixed with other agents.
Practical checks to assess vendor reliability include looking for transparent manufacturing details, third party testing certificates that state the testing laboratory, clear storage and shipping policies, and responsive customer support. None of these checks guarantee safety but they help reduce some supply chain uncertainty.
Clinical guidance and product labeling commonly recommend baseline and periodic testing for people using GH releasing therapies; typical tests include IGF-1, fasting glucose or HbA1c, and a lipid profile, along with routine clinical surveillance for adverse events Egrifta prescribing information. For summaries of safety and dosing see LiverTox tesamorelin entry.
IGF-1 is frequently used as a marker to track biological response, while metabolic tests check for changes in glucose handling or lipids. Monitoring is described in reviews and labeling as a risk management practice, not as proof that long term adverse outcomes are absent Frontiers review.
Decide using four core criteria: regulatory approval for your intended use, strength of the clinical evidence, vendor transparency and product quality, and any rules that apply to you such as sports doping restrictions. For labeled medical indications the presence of an approved product and a defined monitoring pathway is usually decisive.
Use a short checklist to compare options: is the compound approved for your purpose, what trials support that use, can you see independent testing results, and what monitoring would be required. If any of these answers are unclear, treat the option as investigational rather than established.
As a factual point, for a labeled medical indication tesamorelin is the documented option with an approved dose and monitoring guidance while other secretagogues remain investigational with less robust trial evidence and higher sourcing uncertainty Egrifta prescribing information.
The FDA labeled dose for tesamorelin is 2 mg given subcutaneously once daily, a regimen that is stated in the prescribing information and product documents and that is tied to the trials used for approval Egrifta prescribing information.
For off label secretagogues such as sermorelin or ipamorelin, doses reported in practitioner notes or online forums can vary widely because no standardized, evidence based regimens are established for the off label goals commonly discussed. That variability increases uncertainty about safety, expected effects and appropriate monitoring Systematic review.
One common error is assuming online vendor claims equal validated evidence. Marketing language can overstate findings from small or uncontrolled studies. Systematic and narrative reviews caution readers to differentiate between preliminary data and conclusive trial results Frontiers review.
Another pitfall is overlooking the regulatory status and monitoring needs of a compound. For athletes, ignoring doping rules can have career consequences. For anyone using an unapproved product, neglecting baseline and follow up tests can delay detection of metabolic or other adverse effects WADA Prohibited List.
Example: a person with HIV associated abdominal lipodystrophy is evaluated by a clinician who considers tesamorelin because it is the compound with labeled approval for that indication. The clinician would reference the prescribing information, use the 2 mg daily dose if indicated, and arrange baseline and periodic monitoring as described in the label Egrifta prescribing information.
A biohacker interested in off label secretagogues should treat these options as investigational. The right process is to review systematic evidence, verify vendor transparency, plan monitoring for IGF-1 and metabolic tests, and accept there is limited randomized trial support for broad anti aging or general fat loss claims Systematic review.
An athlete must assume that GH secretagogues are prohibited and check the current WADA list and any national federation rules before considering a compound, because positive tests or rule breaches can lead to sanctions WADA Prohibited List.
In short, tesamorelin is the only FDA labeled growth hormone releasing peptide with a specified dose and monitoring pathway, while sermonelin and ipamorelin and similar secretagogues are used off label and have limited high quality trial evidence. Regulators also warn about product quality risks in online markets and sports authorities prohibit secretagogues in competition Egrifta prescribing information.
Next steps: consult the prescribing information for labeled products if you are considering an approved indication, review systematic reviews for evidence summaries, check regulator advisories about online products, and confirm any rules that apply to your activities before acquiring or using any peptide FDA consumer warning.
No. Tesamorelin is approved for HIV associated abdominal lipodystrophy; no growth hormone releasing peptide is FDA approved for general anti aging or routine muscle building.
Current systematic reviews report limited high quality randomized trial evidence for broad fat loss or anti aging claims for sermorelin and ipamorelin.
Look for vendors with clear manufacturing details, third party lab certificates naming the lab, transparent storage and shipping policies, and consult regulator advisories before purchasing.
Bottom line
If you are evaluating peptides for any purpose, use authoritative prescribing information and regulator advisories as primary references. Treat off label uses as investigational and prioritize vendor transparency and appropriate monitoring.
Peptide World provides a centralized product catalog to explore available peptide types and specifications, but catalogs do not replace clinical guidance or regulator information.
The 2-minute quiz sorts the research by what you actually want to achieve, then points you to the guides that apply to you.